Trending Stock News

Rhenman & Partners Asset Management Ab Cut Omnicell (OMCL) Holding By $725,781; 2 Bullish Analysts Covering Hutchison China MediTech Limited (LON:HCM)

Rhenman & Partners Asset Management Ab decreased Omnicell Inc (OMCL) stake by 15.1% reported in 2017Q3 SEC filing. Rhenman & Partners Asset Management Ab sold 14,231 shares as Omnicell Inc (OMCL)’s stock rose 6.09%. The Rhenman & Partners Asset Management Ab holds 80,000 shares with $4.08M value, down from 94,231 last quarter. Omnicell Inc now has $1.66B valuation. The stock decreased 0.45% or $0.2 during the last trading session, reaching $43.85. About 370,315 shares traded or 30.85% up from the average. Omnicell, Inc. (NASDAQ:OMCL) has risen 33.21% since February 21, 2017 and is uptrending. It has outperformed by 16.51% the S&P500.

Among 2 analysts covering Hutchison China Meditech Ltd (LON:HCM), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Hutchison China Meditech Ltd had 33 analyst reports since July 28, 2015 according to SRatingsIntel. Panmure Gordon maintained Hutchison China MediTech Limited (LON:HCM) rating on Monday, December 5. Panmure Gordon has “Buy” rating and GBX 2630 target. The firm earned “Buy” rating on Monday, October 31 by Panmure Gordon. The firm has “Buy” rating by Panmure Gordon given on Friday, September 16. Beaufort Securities maintained the shares of HCM in report on Friday, June 30 with “Buy” rating. The rating was maintained by Beaufort Securities on Wednesday, August 3 with “Buy”. The stock has “Buy” rating by Beaufort Securities on Wednesday, February 14. The company was maintained on Tuesday, March 22 by Beaufort Securities. The stock of Hutchison China MediTech Limited (LON:HCM) earned “Buy” rating by Panmure Gordon on Thursday, May 18. The stock of Hutchison China MediTech Limited (LON:HCM) earned “Buy” rating by Beaufort Securities on Monday, November 2. The rating was maintained by Beaufort Securities with “Buy” on Friday, March 18. See Hutchison China MediTech Limited (LON:HCM) latest ratings:

14/02/2018 Broker: Beaufort Securities Rating: Buy Maintain
29/08/2017 Broker: Panmure Gordon Rating: Buy Old Target: GBX 3840.00 New Target: GBX 3840.00 Maintain

Among 10 analysts covering Omnicell (NASDAQ:OMCL), 7 have Buy rating, 0 Sell and 3 Hold. Therefore 70% are positive. Omnicell had 27 analyst reports since July 31, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Monday, January 29 by Oppenheimer. The stock of Omnicell, Inc. (NASDAQ:OMCL) earned “Buy” rating by Oppenheimer on Friday, October 27. The stock of Omnicell, Inc. (NASDAQ:OMCL) has “Buy” rating given on Thursday, October 26 by Cantor Fitzgerald. PiperJaffray maintained Omnicell, Inc. (NASDAQ:OMCL) rating on Friday, February 2. PiperJaffray has “Neutral” rating and $44 target. Topeka Capital Markets maintained the stock with “Buy” rating in Monday, November 16 report. The rating was maintained by FBR Capital on Friday, October 30 with “Outperform”. Cantor Fitzgerald maintained it with “Buy” rating and $4700 target in Tuesday, July 25 report. Dougherty & Company initiated it with “Buy” rating and $44 target in Thursday, January 19 report. The firm has “Buy” rating given on Thursday, October 19 by Oppenheimer. The firm has “Hold” rating by Piper Jaffray given on Friday, July 28.

Rhenman & Partners Asset Management Ab increased Aerie Pharmaceuticals Inc (NASDAQ:AERI) stake by 45,932 shares to 120,932 valued at $5.88M in 2017Q3. It also upped Rigel Pharmaceuticals Inc (NASDAQ:RIGL) stake by 974,100 shares and now owns 2.35M shares. Horizon Pharma Plc (NASDAQ:HZNP) was raised too.

Since September 1, 2017, it had 0 insider purchases, and 4 insider sales for $883,828 activity. 1,926 Omnicell, Inc. (NASDAQ:OMCL) shares with value of $99,559 were sold by Kuipers Peter J.. Another trade for 1,000 shares valued at $51,734 was sold by PETERSMEYER GARY S. $552,537 worth of Omnicell, Inc. (NASDAQ:OMCL) shares were sold by LIPPS RANDALL A.

Analysts await Omnicell, Inc. (NASDAQ:OMCL) to report earnings on May, 3. They expect $-0.04 EPS, up 86.21% or $0.25 from last year’s $-0.29 per share. After $0.28 actual EPS reported by Omnicell, Inc. for the previous quarter, Wall Street now forecasts -114.29% negative EPS growth.

Investors sentiment decreased to 1.02 in 2017 Q3. Its down 0.41, from 1.43 in 2017Q2. It fall, as 8 investors sold OMCL shares while 79 reduced holdings. 29 funds opened positions while 60 raised stakes. 37.10 million shares or 0.94% less from 37.45 million shares in 2017Q2 were reported. Timpani Capital Mgmt Limited Liability Co reported 1.24% in Omnicell, Inc. (NASDAQ:OMCL). Comerica Retail Bank holds 76,632 shares or 0.03% of its portfolio. Texas Yale Capital has 0.08% invested in Omnicell, Inc. (NASDAQ:OMCL). 107,910 are owned by Martingale Asset L P. Ubs Asset Americas has 0.01% invested in Omnicell, Inc. (NASDAQ:OMCL). Champlain Invest Ltd Llc stated it has 1.47 million shares. Amalgamated Bank holds 0.01% or 5,049 shares in its portfolio. 1492 Capital Mgmt Ltd has invested 0.77% in Omnicell, Inc. (NASDAQ:OMCL). Snyder Management Limited Partnership holds 226,558 shares. Barclays Public Llc stated it has 0% of its portfolio in Omnicell, Inc. (NASDAQ:OMCL). Castleark Mgmt Limited Liability holds 0.3% or 185,305 shares. Needham Inv Management Lc holds 0.17% in Omnicell, Inc. (NASDAQ:OMCL) or 13,000 shares. Glenmede Trust Na owns 755,927 shares. 4,525 were reported by Marco Inv Management Lc. Price T Rowe Associate Md has invested 0.01% of its portfolio in Omnicell, Inc. (NASDAQ:OMCL).

Leave a Reply

Your email address will not be published. Required fields are marked *